Related Experiment Video
Updated: Jul 18, 2026

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis
Published on: August 11, 2010
Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect
H Morisaki1, T Morisaki, L K Newby
1Seymour Gray Molecular Medicine Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia 19104-4283.
Abstract:
Approximately 2% of Caucasians and African-Americans are homozygous for a nonsense mutation in exon 2 of the AMPD1 (AMP deaminase) gene. These individuals have a high grade deficiency of AMPD activity in their skeletal muscle. More than 100 patients with AMPD1 deficiency have been reported to have symptoms of a metabolic myopathy, but it is apparent many individuals with this inherited defect are asymptomatic given the prevalence of this mutant. Results of the present study provide a potential molecular explanation for "correction" of this genetic defect. Alternative splicing eliminates exon 2 in 0.6-2% of AMPD1 mRNA transcripts in adult skeletal muscle. Expression studies document that AMPD1 mRNA, which has exon 2 deleted, encodes a functional AMPD peptide. A much higher percentage of alternatively spliced transcripts are found during differentiation of human myocytes in vitro. Transfection studies with human minigene constructs demonstrate that alternative splicing of the primary transcript of human AMPD1 is controlled by tissue-specific and stage-specific signals. Alternative splicing of exon 2 in individuals who have inherited this defect provides a mechanism for phenotypic rescue and variations in splicing patterns may contribute to the variability in clinical symptoms.
Insights
Genetic variations in the AMPD1 gene can cause metabolic myopathy. Alternative splicing of AMPD1 mRNA in skeletal muscle may correct this defect, explaining asymptomatic cases and symptom variability.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- A nonsense mutation in exon 2 of the AMPD1 gene affects 2% of Caucasians and African-Americans, leading to skeletal muscle AMP deaminase deficiency.
- While over 100 patients exhibit symptoms of metabolic myopathy, many individuals with this defect remain asymptomatic, suggesting a compensatory mechanism.
Purpose of the Study:
- To investigate the molecular basis for the "correction" of the genetic defect caused by AMPD1 mutations.
- To explore the role of alternative splicing in the AMPD1 gene and its impact on AMP deaminase activity and clinical presentation.
Main Methods:
- Analysis of AMPD1 mRNA transcripts in adult skeletal muscle and differentiating human myocytes.
- Expression studies using AMPD1 mRNA lacking exon 2 to assess peptide functionality.
- Transfection studies with human minigene constructs to identify regulatory signals for alternative splicing.
Main Results:
- Alternative splicing, deleting exon 2, occurs in 0.6-2% of adult skeletal muscle AMPD1 mRNA transcripts.
- AMPD1 mRNA lacking exon 2 encodes a functional AMP deaminase peptide.
- Alternative splicing is significantly higher during in vitro myocyte differentiation and is regulated by tissue-specific and stage-specific signals.
Conclusions:
- Alternative splicing of exon 2 in the AMPD1 gene provides a mechanism for phenotypic rescue in individuals with the inherited defect.
- Variations in alternative splicing patterns may contribute to the observed variability in clinical symptoms among individuals with AMPD1 deficiency.
More Related Videos
Related Concept Videos
RNA Splicing
In-vitro Mutagenesis
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...

